DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended March 31, 2024.
“We achieved our eighth consecutive quarter of revenue growth putting us on a run rate of over $250 million in revenue for 2024,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In the last week, we received Fast Track designation and clearance of the IND for MNKD-101 which may allow us to bring this innovative product to patients more quickly.”
Revenue Highlights
| Three Months Ended March 31, | ||||||||||||||||
| 2024 | 2023 | $ Change | % Change | |||||||||||||
| (Dollars in thousands) | ||||||||||||||||
| Royalties – collaborations | $ | 22,651 | $ | 11,678 | $ | 10,973 | 94 | % | ||||||||
| Revenue – collaborations and services | 24,848 | 11,386 | $ | 13,462 | 118 | % | ||||||||||
| Net revenue – Afrezza | 14,438 | 12,423 | $ | 2,015 | 16 | % | ||||||||||
| Net revenue – V-Go | 4,326 | 5,139 | $ | (813 | ) | (16 | %) | |||||||||
| Total revenues | $ | 66,263 | $ | 40,626 | $ | 25,637 | 63 | % | ||||||||
Royalties related to Tyvaso DPI for the first quarter of 2024 increased $11.0 million, or 94%, due to increased patient demand. Collaborations and services revenue increased $13.5 million, or 118%, compared to the same period in 2023 primarily attributable to an increase in manufacturing Tyvaso DPI for United Therapeutics ("UT"). Afrezza® net revenue for the first quarter of 2024 increased $2.0 million, or 16%, compared to the same period in 2023 as a result of higher price (including a decrease in gross-to-net adjustments). V-Go® net revenue for the first quarter of 2024 decreased $0.8 million, or 16%, compared to the same period in 2023 as a result of lower product demand.
Commercial product gross margin in the first quarter of 2024 was 80% compared to 69% for the same period in 2023. The increase in gross margin was primarily attributable to an increase in Afrezza net revenue.
Cost of revenue – collaborations and services for the first quarter of 2024 was $14.8 million compared to $10.7 million for the same period in 2023. The $4.1 million increase was primarily attributable to increased manufacturing volume and related production activities. Higher manufacturing volumes resulted in efficiencies which contributed to a lower effective cost per unit.
Research and development ("R&D") expenses for the first quarter of 2024 were $10.0 million compared to $5.6 million for the same period in 2023. The $4.4 million increase was primarily attributed to increased development activities for clofazimine inhaled suspension (MNKD-101), costs for an Afrezza post-marketing clinical study (INHALE-3) which commenced in the second quarter of 2023 and personnel expenses due to increased headcount.
Selling expenses were $11.6 million in the first quarter of 2024 compared to $13.3 million for the same period in 2023. The $1.7 million decrease was primarily due to reduced personnel and travel expenses related to sales force restructuring activities completed during the quarter.
General and administrative expenses for the first quarter of 2024 were $10.7 million compared to $10.5 million for the same period in 2023. The $0.2 million increase was primarily attributable to a loss of $1.2 million related to estimated returns associated with sales of V-Go that pre-date our acquisition of the product, partially offset by reduced personnel costs.
Interest income, net, was $3.4 million for the first quarter of 2024 compared to $1.3 million for the same period in 2023. The $2.1 million increase was primarily due to higher yields on our securities portfolio and an increase in the underlying investments from the proceeds of the sale of 1% of our Tyvaso DPI royalties in December 2023.
Interest expense on notes was $2.6 million and interest expense on financing liability (related to the sale-leaseback of our Danbury manufacturing facility) was $2.4 million for the first quarter of 2024 and remained consistent with the same period in 2023.
Interest expense on liability for sale of future royalties was $4.2 million for the first quarter of 2024 due to imputed interest and amortization of debt issuance costs on the liability recorded in connection with the sale of a portion of our future royalties in December 2023.
Cash, cash equivalents and investments as of March 31, 2024 were $304.5 million.
Non-GAAP Measures
To supplement our condensed consolidated financial statements presented under U.S. generally accepted accounting principles ("GAAP"), we are presenting non-GAAP net income (loss) and non-GAAP net income (loss) per share - diluted, which are non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by us in this report have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to similarly titled measures used by other companies.
The following table reconciles our financial measure for net income (loss) and net income (loss) per share ("EPS") for diluted weighted average shares as reported in our condensed consolidated statements of operations to a non-GAAP presentation as adjusted for select non-cash items: 1% royalty on net revenues for Tyvaso DPI ("sold portion of royalty revenue") and interest expense on the related liability, stock-based compensation expense and (gain) loss on foreign currency transaction for the periods presented:
| Three Months | |||||||||||||||
| Ended March 31, | |||||||||||||||
| 2024 | 2023 | ||||||||||||||
| Net Income | Diluted EPS | Net Loss | Diluted EPS | ||||||||||||
| (In thousands except per share data) | |||||||||||||||
| GAAP reported | $ | 10,630 | $ | 0.04 | $ | (9,795 | ) | $ | (0.04 | ) | |||||
| Select non-cash adjustments: | |||||||||||||||
| Sold portion of royalty revenue (1) | (2,265 | ) | (0.01 | ) | — | — | |||||||||
| Interest expense on liability for sale of future royalties | 4,248 | 0.01 | — | — | |||||||||||
| Stock compensation | 3,885 | 0.01 | 3,655 | 0.01 | |||||||||||
| (Gain) loss on foreign currency transaction | (1,399 | ) | — | 954 | 0.01 | ||||||||||
| Non-GAAP adjusted | $ | 15,099 | $ | 0.05 | $ | (5,186 | ) | $ | (0.02 | ) | |||||
| Weighted average shares used to compute net income (loss) per share – diluted | 324,733 | 263,969 | |||||||||||||
__________________________
(1) Represents the non-cash portion of the 1% royalty on net sales of Tyvaso DPI earned during 1Q 2024 which is remitted to the royalty purchaser and recognized as royalties from collaborations in our consolidated statements of operations. Our revenues from royalties from collaborations during 1Q 2024 totaled $22.7 million, of which $2.3 million will be remitted to the royalty purchaser.
Clinical Development Update
Afrezza INHALE-1 (pediatric phase 3 clinical trial)
Afrezza INHALE-3 (T1DM, Afrezza vs. standard of care including AID pumps; phase 4 clinical trial)
MNKD-101 (clofazimine inhalation suspension)
MNKD-201 (nintedanib DPI)
Conference Call
MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at mannkindcorp.com under Events & Presentations. A replay will be available on MannKind's website for 14 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
Forward-Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the expected timing of patient enrollment and dosing in clinical studies of MNKD-101 and MNKD-201; the potential for expedited review of a regulatory submission for MNKD-101 and the potential to bring MNKD-101 to patients more quickly; expected timing for data read-outs for clinical studies of MNKD-201 and Afrezza; and the timing of planned FDA submissions for Afrezza. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with manufacturing and supply, risks associated with developing product candidates, risks and uncertainties related to unforeseen delays that may impact the timing of progressing clinical trials and reporting data, risks associated with safety and other complications of our products and product candidates; risks associated with the regulatory review process; and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 27, 2024, as updated by the "Risk Factors" in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Tyvaso DPI is a trademark of United Therapeutics Corporation.
AFREZZA, MANNKIND, and V-GO are registered trademarks of MannKind Corporation.
MannKind Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
This email address is being protected from spambots. You need JavaScript enabled to view it.
| MANNKIND CORPORATION AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| (In thousands except per share data) | ||||||||
| Revenues: | ||||||||
| Net revenue – commercial product sales | $ | 18,764 | $ | 17,562 | ||||
| Revenue – collaborations and services | 24,848 | 11,386 | ||||||
| Royalties – collaborations | 22,651 | 11,678 | ||||||
| Total revenues | 66,263 | 40,626 | ||||||
| Expenses: | ||||||||
| Cost of goods sold | 3,819 | 5,530 | ||||||
| Cost of revenue – collaborations and services | 14,779 | 10,683 | ||||||
| Research and development | 10,013 | 5,605 | ||||||
| Selling | 11,601 | 13,310 | ||||||
| General and administrative | 10,728 | 10,542 | ||||||
| (Gain) loss on foreign currency transaction | (1,399 | ) | 954 | |||||
| Total expenses | 49,541 | 46,624 | ||||||
| Income (loss) from operations | 16,722 | (5,998 | ) | |||||
| Other income (expense): | ||||||||
| Interest income, net | 3,434 | 1,302 | ||||||
| Interest expense on financing liability | (2,447 | ) | (2,424 | ) | ||||
| Interest expense | (2,567 | ) | (2,786 | ) | ||||
| Interest expense on liability for sale of future royalties | (4,248 | ) | — | |||||
| Other income | — | 111 | ||||||
| Total other expense | (5,828 | ) | (3,797 | ) | ||||
| Income (loss) before income tax expense | 10,894 | (9,795 | ) | |||||
| Income tax expense | 264 | — | ||||||
| Net income (loss) | $ | 10,630 | $ | (9,795 | ) | |||
| Net income (loss) per share – basic | $ | 0.04 | $ | (0.04 | ) | |||
| Weighted average shares used to compute net income (loss) per share – basic | 270,356 | 263,969 | ||||||
| Net income (loss) per share – diluted | $ | 0.04 | (1) | $ | (0.04 | ) | ||
| Weighted average shares used to compute net income (loss) per share – diluted | 324,733 | (2) | 263,969 | |||||
__________________________
(1) The calculation of diluted EPS includes an add back of interest expense to net income which represents interest that would not be recognized if the conversion of our Senior convertible notes and Mann Group convertible note were converted to shares of our common stock. The related interest expense for 1Q 2024 was $1,856 and resulted in adjusted net income of $12,486. These adjustments are only applied to periods with net income.
(2) Diluted weighted average shares differs from basic due to the weighted average number of shares that would be outstanding upon conversion of our Senior convertible notes (44,120 shares) and Mann Group convertible note (3,370 shares), and exercise or vesting of outstanding share-based payments to employees (6,887 shares). These adjustments to weighted average shares are only applied to periods with net income.
| MANNKIND CORPORATION AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| March 31, 2024 | December 31, 2023 | |||||||
| (In thousands except share and per share data) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 193,272 | $ | 238,480 | ||||
| Short-term investments | 107,457 | 56,619 | ||||||
| Accounts receivable, net | 19,912 | 14,901 | ||||||
| Inventory | 26,442 | 28,545 | ||||||
| Prepaid expenses and other current assets | 36,019 | 34,848 | ||||||
| Total current assets | 383,102 | 373,393 | ||||||
| Property and equipment, net | 83,620 | 84,220 | ||||||
| Goodwill | 1,931 | 1,931 | ||||||
| Other intangible asset | 1,053 | 1,073 | ||||||
| Long-term investments | 3,726 | 7,155 | ||||||
| Other assets | 7,447 | 7,426 | ||||||
| Total assets | $ | 480,879 | $ | 475,198 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,149 | $ | 9,580 | ||||
| Accrued expenses and other current liabilities | 42,291 | 42,036 | ||||||
| Financing liability – current | 9,872 | 9,809 | ||||||
| Midcap credit facility – current | 20,000 | — | ||||||
| Liability for sale of future royalties – current | 10,537 | 9,756 | ||||||
| Deferred revenue – current | 7,601 | 9,085 | ||||||
| Recognized loss on purchase commitments – current | 2,446 | 3,859 | ||||||
| Total current liabilities | 99,896 | 104,125 | ||||||
| Mann Group convertible note | 8,829 | 8,829 | ||||||
| Accrued interest – Mann Group convertible note | 55 | 56 | ||||||
| Financing liability – long term | 94,207 | 94,319 | ||||||
| Midcap credit facility – long term | 8,105 | 13,019 | ||||||
| Senior convertible notes | 227,214 | 226,851 | ||||||
| Liability for sale of future royalties – long term | 137,418 | 136,054 | ||||||
| Recognized loss on purchase commitments – long term | 60,287 | 60,942 | ||||||
| Operating lease liability | 3,645 | 3,925 | ||||||
| Deferred revenue – long term | 67,741 | 69,794 | ||||||
| Milestone liabilities | 3,452 | 3,452 | ||||||
| Total liabilities | 710,849 | 721,366 | ||||||
| Stockholders' deficit: | ||||||||
| Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2024 or December 31, 2023 | — | — | ||||||
| Common stock, $0.01 par value – 800,000,000 shares authorized; 270,801,781 and 270,034,495 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 2,703 | 2,700 | ||||||
| Additional paid-in capital | 2,986,104 | 2,980,539 | ||||||
| Accumulated deficit | (3,218,777 | ) | (3,229,407 | ) | ||||
| Total stockholders' deficit | (229,970 | ) | (246,168 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 480,879 | $ | 475,198 | ||||
| Last Trade: | US$6.80 |
| Daily Change: | -0.22 -3.13 |
| Daily Volume: | 5,144,699 |
| Market Cap: | US$1.870B |
November 07, 2024 November 05, 2024 November 04, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
